SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.
How Does SS-31 Work in the Body?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics.
Understanding its mechanism of action helps researchers design protocols and predict outcomes.
What Is the Primary Mechanism of SS-31?
Selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and enhancing electron transfer efficiency. Reduces cytochrome C peroxidase activity, decreases reactive oxygen species production, increases ATP generation, and prevents apoptosis through mitochondrial outer membrane stabilization.
This mechanism operates at the cellular level and influences downstream pathways that produce the observable effects researchers study.
What Biological Pathways Does SS-31 Affect?
As a Mitochondrial-targeting tetrapeptide, SS-31 interacts with specific receptors and signaling cascades. These pathways are responsible for the compound's effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
The multi-pathway activity is what gives SS-31 its broad potential application range — each pathway contributes to different aspects of the overall effect profile.
How Quickly Does SS-31's Mechanism Take Effect?
With a half-life of approximately 20-30 minutes, SS-31 begins interacting with its target receptors within minutes of administration. However, the downstream biological effects take longer to manifest — typically days to weeks depending on the application.
Standard cycles run 12-48 weeks in clinical trials because that's the timeframe needed for the mechanism to produce measurable, cumulative results.
What Does the Research Say?
FDA-approved September 2025 for Barth syndrome (as FORZINITY). Phase 3 TAZPOWER trial showed improved muscle strength and cardiac function. Phase 3 ongoing for primary mitochondrial myopathy. Robust preclinical evidence in heart failure, aging, renal disease, and neurodegeneration.
The first FDA-approved mitochondrial-targeted therapy — directly addressing the fundamental mitochondrial dysfunction underlying multiple age-related and genetic diseases by stabilizing the inner membrane structure itself.
Bottom Line on SS-31's Mechanism
SS-31 works through mitochondrial-targeting tetrapeptide activity to influence improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction. Its mechanism involves multiple pathways, which is why it shows potential across several research applications.
See our SS-31 benefits guide for how this mechanism translates to practical outcomes.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Stacking Guide
- SS-31 Cycle Guide
- SS-31 Research
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.